{
    "clinical_study": {
        "@rank": "141105", 
        "acronym": "ALIGN", 
        "arm_group": {
            "arm_group_label": "annuloplasty", 
            "arm_group_type": "Experimental", 
            "description": "All patients will receive treatment with the Mitralign Percutaneous Annuloplasty System (MPAS)."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to test the safety and device performance of the Mitralign\n      system (\"MPAS\") to treat functional mitral valve regurgitation."
        }, 
        "brief_title": "Mitralign Percutaneous Annuloplasty System for Chronic Functional Mitral Valve Regurgitation", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Mitral Valve Regurgitation", 
        "condition_browse": {
            "mesh_term": "Mitral Valve Insufficiency"
        }, 
        "detailed_description": {
            "textblock": "The ALIGN study is a single arm, prospective study.  The objective of the study is to\n      investigate the safety and performance of a catheter-based plication device intended to\n      reduce the circumference of the dilated mitral valve.  The study will enroll up to 50\n      subjects from up to 5 sites (Paraguay, Columbia, Dominican Republic, Brazil, and India) who\n      will be followed for 36 months post index procedure. Enrollment is defined at the time the\n      study device is inserted into the body and patients will be followed at 30 days, and Months\n      6, 12, 24 and 36  post index procedure."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  NYHA II-IV\n\n          -  Structurally normal mitral valve\n\n          -  At least Grade 2 mitral regurgitation\n\n          -  Left ventricular ejection fraction not less than 20% and not greater than 45%\n\n          -  Left ventricular end diastolic diameter not less than 5.0 cm and not greater than 7.5\n             cm\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating female\n\n          -  Mitral stenosis\n\n          -  Mod/severe aortic stenosis or regurgitation\n\n          -  Mod/severe tricuspid stenosis or regurgitation\n\n          -  Endocarditis\n\n          -  Previous mitral valve repair or MV replacement\n\n          -  Bioprosthetic or mechanical aortic valve\n\n          -  Known unstable angina or MI within 30 days prior to procedure\n\n          -  CVA within past 6 months\n\n          -  Known contraindications to blood transfusion, contrast dye, DAPT"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01740583", 
            "org_study_id": "CLPR-007"
        }, 
        "intervention": {
            "arm_group_label": "annuloplasty", 
            "description": "plication of the mitral valve annulus", 
            "intervention_name": "percutaneous annuloplasty", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "mitral valve, regurgitation, annuloplasty", 
        "lastchanged_date": "December 4, 2012", 
        "location": {
            "contact": {
                "email": "adrian@ebner.com.py", 
                "last_name": "Adrian Ebner, M.D.", 
                "phone": "011 595 21 296 727"
            }, 
            "facility": {
                "address": {
                    "city": "Asuncion", 
                    "country": "Paraguay"
                }, 
                "name": "Sanatorio Italiano"
            }, 
            "investigator": {
                "last_name": "Santiago Gallo, M.D.", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Paraguay"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Feasibility Study of the Mitralign Annuloplasty System for the Treatment of Chronic Functional Mitral Valve Regurgitation", 
        "overall_contact": {
            "email": "egmitter@mitralign.com", 
            "last_name": "Emily Gmitter", 
            "phone": "978-863-2401"
        }, 
        "overall_contact_backup": {
            "email": "jfoss@mitralign.com", 
            "last_name": "Jenifer Foss", 
            "phone": "978-863-2445"
        }, 
        "overall_official": {
            "affiliation": "Sanatorio Italiano (The Italian Hospital)", 
            "last_name": "Adrian Ebner, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Paraguay: Ministerio de Salud P\u00fablica y Bienestar Social", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "MAE defined as occurrence of any of the following: Mitral valve-related surgery/intervention, myocardial infarction, cardiac tamponade, stroke, device and/or procedure-related death", 
            "measure": "Major Adverse Events (MAE)", 
            "safety_issue": "Yes", 
            "time_frame": "within 30 days post procedure"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01740583"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Freedom from an increase in ventricular diameter", 
            "measure": "Echocardiographic Outcomes", 
            "safety_issue": "No", 
            "time_frame": "at 6 months"
        }, 
        "source": "Mitralign, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mitralign, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}